ChiCTR2600127200 Trastuzumab Rezetecan Locally advanced breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready landscape. This focused report examines ChiCTR2600127200—NeoTRECAMCT-01：A prospective, non-randomized controlled clinical study of SHR-A1811 plus camrelizumab in perioperative combination or sequential chemotherapy for ER(-)/ER(1-10%), HER2-low expressing early or locally advanced breast cancer—using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, Drug & Asset MCP for mechanism and development context, and Company & Deal Intelligence MCP for sponsor background. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 20 July 2026; publication date: 20 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why ChiCTR2600127200 is a hot trial to watch

Locally advanced breast cancer is increasingly segmented by mechanism, biomarker, treatment setting, geography and endpoint architecture. ChiCTR2600127200 is notable because it evaluates Trastuzumab Rezetecan in a Phase 2 design while Postoperative pathology assessment serves as the main decision variable. The critical question is whether the protocol can convert its rationale into a clinically interpretable and operationally credible readout.

PatSnap Clinical Trials MCP makes protocol fields machine-readable, while the companion asset and organization servers add development-status, target and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The phase label is only the starting point. Allocation is Non-Randomized, masking is NA, and the intervention model is Not reported. Planned enrollment of 37 participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Primary: Postoperative pathology assessment (At surgery post-neoadjuvant therapy)
• Secondary: Adverse events (AEs) and serious adverse events (SAEs) graded according to NCI CTCAE v5.0; monitoring of vital signs, physical examination, laboratory tests (complete blood count, blood chemistry, urinalysis, thyroid function, cardiac enzymes, etc.), electrocardiogram (QTcF), immune-related adverse events, etc. (From informed consent through 30 days after last dose)
• Secondary: Ki-67 index assessed by immunohistochemistry (IHC); percentage of Ki-67-positive tumor cells. Change = post-treatment value minus baseline value. (Baseline (pre-treatment core biopsy) and at surgery after neoadjuvant therapy)
• Secondary: Radiological assessment per RECIST v1.1; ORR defined as proportion of patients achieving complete response (CR) or partial response (PR). (After neoadjuvant therapy)
• Secondary: Breast-conserving rate = (Number of patients undergoing breast-conserving surgery) / (Total number of patients who received surgery) × 100%. Breast-conserving surgery is defined as complete tumor resection with negative margins while preserving the majority of the breast contour. (After surgery)

Benchmark readouts in the surrounding field

• Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer (Phase 3): Cycle 1(Mean) = 4.51 units on a scale (Standard Error, 0.155); Cycle 1(Mean) = 4.93 units on a scale (Standard Error, 0.141)
• A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide, or Tirzepatide for the Treatment of Obesity (Phase 2): Incremental Postprandial Triglycerides (TG)(Mean) = 43.81 percent change (Standard Deviation, 92.373); Incremental Postprandial Triglycerides (TG)(Mean) = -51.91 percent change (Standard Deviation, 72.293)
• A Phase II Study to Evaluate the Delay in Ovulation Following Oral Levonorgestrel Plus Meloxicam Compared to Placebo in Obese But Normal Menstruating Women (Phase 2): Interval From First Dose to Evidence of Ovulation.(Mean) = 2.67 Number of days (Standard Deviation, 1.53); Interval From First Dose to Evidence of Ovulation.(Mean) = 4.0 Number of days (Standard Deviation, 0)

These indexed results are contextual benchmarks, not direct head-to-head evidence. Population, treatment line, endpoint definitions, follow-up and analysis sets may differ. Their value is to clarify the type and magnitude of evidence already visible in the competitive landscape.

Build a living trial monitor: connect to PatSnap MCP Servers and track status changes, endpoint revisions, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Trastuzumab Rezetecan (Approved; HER2 x Top I); Carboplatin (Approved; DNA); Docetaxel (Approved; Tubulin)

Company & Deal Intelligence context: First Affiliated Hospital of Xi'an Jiaotong University — China — http://www.dyyy.xjtu.edu.cn

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can decide whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Sequencing evidence: comparative data after the most relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter probability of success before a headline data release.

Bottom line

ChiCTR2600127200 is a focused lens on Locally advanced breast cancer development. Its value will be determined by whether Trastuzumab Rezetecan can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from indexed benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.